TSBX

About Turnstone Biologics Corp.

Turnstone Biologics Corp. is a clinical-stage biotechnology firm dedicated to developing therapeutic and curative treatments for patients battling solid tumor cancers. Its leading investigational drug, TIDAL-01, is currently undergoing Phase 1 clinical trials for indications such as breast cancer, colorectal cancer, and uveal melanoma. This compound is also being assessed in an investigator-sponsored trial to address cutaneous and non-cutaneous melanomas. Furthermore, the company is advancing TIDAL-02, which is in preclinical development for treating various solid tumors. Turnstone Biologics was established in 2014 and maintains its headquarters in La Jolla, California.

CEO: Sammy J. Farah
IPO Date: Jul 21, 2023

Market Data

Open: $0.355
High: $0.355
Low: $0.355
Volume: 283.8K
Avg Volume: 404.9K
52W High: $2.26
52W Low: $0.29

Valuation

Market Cap: $8.2M
Enterprise Value: $-8.1M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-68M
Revenue: $0
Net Income: $-71M
Cash: $29M
Debt: $1.2M

Events

EarningsAug 8

EPS est. -0.16 · actual -0.24